<DOC>
	<DOCNO>NCT00890435</DOCNO>
	<brief_summary>RATIONALE : Gathering information patient guardian agree decline participate optional pharmacokinetic portion phase I treatment study may help doctor plan clinical trial future . PURPOSE : This clinical trial look decision make participate pharmacokinetic study patient enrol phase I treatment clinical trial .</brief_summary>
	<brief_title>Decision Making About Participating Pharmacokinetic Studies Patients Enrolled Phase I Treatment Clinical Trial</brief_title>
	<detailed_description>OBJECTIVES : - To use simple 2-page survey gather preliminary information patient parents/guardians ( patient minor ) agree participate optional pharmacokinetic portion phase I treatment study consent participate phase I treatment study . OUTLINE : This multicenter study . Patients parents/guardians ( patient minor ) complete short questionnaire reason agreeing/declining participation optional pharmacokinetic sample component phase I clinical trial . Patient demographic relevant information collect .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients parents/guardians ( patient minor ) consent participate phase I treatment clinical trial optional pharmacokinetic ( PK ) component , within past 4 week Must withdrawn consent phase I treatment study Patients parents/guardians eligible regardless whether initially agree participate PK sample Must withdraw consent PK sample prior complete study questionnaire initially agree optional PK sampling Patients parents/guardians eligible regardless whether actually complete PK sample ( provide reason complete sample withdrawal initial consent phase I treatment study ) PATIENT CHARACTERISTICS : Not cognitively physically impaired May participate study questionnaire survey PRIOR CONCURRENT THERAPY : No limit participation number prior phase I trials study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood ependymoblastoma</keyword>
	<keyword>childhood medulloepithelioma</keyword>
	<keyword>childhood meningioma</keyword>
	<keyword>childhood mixed glioma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>adult astrocytic tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>adult ependymal tumor</keyword>
	<keyword>adult meningeal tumor</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult oligodendroglial tumor</keyword>
	<keyword>adult pineal parenchymal tumor</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>